Experimental T-cell therapy for severe autoimmune diseases
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Heart & circulation, Immune system & allergy, Skin clinical trials.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an autoimmune disease that has not responded to treatment or has come back (like lupus, autoimmune anemia, or myasthenia gravis).
- A blood test must show that your B cells have a marker called CD19.
- Your major organs (bone marrow, liver, kidneys) must be working well enough.
- You should be able to do daily activities mostly on your own.
- You must not be pregnant and must agree to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This study tests a new cell therapy called CD19 UCAR-T. It is being studied for people with certain severe autoimmune conditions that have not improved with regular treatments. The goal is to see if this therapy can help control the immune system and improve symptoms.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.